Comparative Pharmacology
Head-to-head clinical analysis: FOLICET versus HEXA BETALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLICET versus HEXA BETALIN.
FOLICET vs HEXA-BETALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folic acid is reduced to tetrahydrofolate (THF) through the enzyme dihydrofolate reductase. THF is a cofactor in one-carbon transfer reactions involved in purine and pyrimidine synthesis, and amino acid metabolism, essential for DNA synthesis and cell division.
Hexa-Betalin is a combination of six B vitamins (B1, B2, B3, B5, B6, B12) that act as cofactors in various enzymatic reactions involved in energy metabolism, neurotransmitter synthesis, and nerve function.
1 mg orally once daily. For treatment of megaloblastic anemia, up to 5 mg daily initially.
Dosage forms: Tablet 10mg, 50mg, 100mg, 250mg; Injection 50mg/mL. Usual adult dose: 100–250mg orally 1–3 times daily. Maximum 1000mg/day. IV/IM: 50–250mg every 6–8 hours as needed.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in adults with normal renal function; may be prolonged up to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 3-5 hours in patients with normal renal function. This short half-life necessitates frequent dosing for sustained therapeutic effect. Half-life is prolonged in renal impairment.
Primarily renal elimination: approximately 80% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal excretion accounts for <15%.
Renal excretion of unchanged drug accounts for 75-85% of the administered dose. Biliary/fecal elimination is minimal, less than 5%.
Category C
Category C
Vitamin
Vitamin